Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes
Endocrine-Related Cancer · 2024
DOI: 10.1530/erc-24-0064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Marta García-Goñi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Thyroid Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
A common immune-related adverse event (irAE) with immune checkpoint inhibitors (ICIs) is thyroid dysfunction (TD-irAEs). The clinical presentation can be varied, and its association with prognosis remains unclear. We investigated the characteristics of TD-irAEs and their association with clinical outcomes among cancer patients treated with ICIs in a real-life setting. Response to treatment was assessed using RECIST v1.1. We calculated the probability of recurrence and survival associated with TD-irAEs using multivariable-adjusted regression and Cox proportional hazards models. In this single-center retrospective analysis, we included 238 patients (72% male) with a median age of 69.5 years. Primary tumors were melanoma (23.1%), lung (60.5%), or urothelial cancer (16.4%), treated with atezolizumab (23.1%), pembrolizumab (44.5%), ipilimumab (0.4%), and/or nivolumab (25.6%). Seventy (29%) patients developed TD-irAEs in a median time of 69 days (41–181). The incidence of TD-irAEs with combination therapy was higher than with monotherapy (67% vs 6.3%, P = 0.011). TD-irAE patients showed a higher objective response rate (ORR) than those without TD-irAEs (60% vs 42.3%, P = 0.013) and longer overall survival (OS) 45 vs 16 months, P < 0.006. Patients who developed TD-irAEs had a relative reduction of 77% (OR 0.23, 95% CI 0.11–0.47) in the risk of progression and of 47% in the risk of mortality (HR 0.53, 95% CI 0.36–0.80), independent of age, sex, primary tumor, or ICI regimen. TD-irAEs occur in nearly 30% of our patients receiving ICIs. In our analysis, TD-irAEs appeared to be associated with higher ORR and longer OS and showed a reduction in the risk of progression and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, University of Navarra, Pamplona, Spain.
- Department of Oncology, University of Navarra, Pamplona, Spain.
- IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain.
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
- CIBER de Fisiopatología de la Obesidad y la Nutrición, Pamplona, Spain.
ORCID-Profile: Marta García-Goñi, Juan C Galofré
Zitieren
APA
García-Goñi, M., Vázquez Gutiérrez, B., Sanmamed, M. F., Martín-Algarra, S., Luis Pérez-Gracia, J., Olmedo, M., Chumbiauca, E., Martín-Calvo, N., & Galofré, J. C. (2024). Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0064
Vancouver
García-Goñi M, Vázquez Gutiérrez B, Sanmamed MF, Martín-Algarra S, Luis Pérez-Gracia J, Olmedo M, et al. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes. Endocrine-Related Cancer. 2024. doi:10.1530/erc-24-0064
BibTeX
@article{GarcaGoi2024,
author = {García-Goñi, Marta and Vázquez Gutiérrez, Beatriz and Sanmamed, Miguel F and Martín-Algarra, Salvador and Luis Pérez-Gracia, José and Olmedo, María and Chumbiauca, Estefanía and Martín-Calvo, Nerea and Galofré, Juan C},
title = {Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes},
journal = {Endocrine-Related Cancer},
year = {2024},
doi = {10.1530/erc-24-0064}
}
EUVIMED